‘Not at all what I had expected’: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study-Reference-Cited by-同舟云学术

‘Not at all what I had expected’: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study

Published:2021-11 Issue: Volume: Page:108667
ISSN:0740-5472
Container-title:Journal of Substance Abuse Treatment
language:en
Short-container-title:Journal of Substance Abuse Treatment

Author:

Brenna Ida Halvorsen,Marciuch Anne,Birkeland Bente,Veseth Marius,Røstad Bente,Løberg Else-Marie,Solli Kristin Klemmetsby,Tanum Lars,Weimand Bente

Funder

Norges Forskningsråd

South-Eastern Norway Regional Health Authority

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology,Medicine (miscellaneous),Pshychiatric Mental Health

Reference114 articles.

1. The rise and fall of kappa-opioid receptors in drug abuse research;Banks;Handbook of experimental pharmacology,2020

2. Participants' treatment perspectives on a clinical trial on the use of extended-release naltrexone for substance use disorders: Considerations for future clinical research;Bardwell;Journal of Addiction Medicine,2020

3. Maintenance medication for opiate addiction: The foundation of recovery;Bart;Journal of Addictive Diseases,2012

4. Peer-delivered recovery support Services for Addictions in the United States: A systematic review;Bassuk;Journal of Substance Abuse Treatment,2016

5. Scientific realism and human emancipation;Bhaskar,2009

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ‘Matters-of-concern’ associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study;International Journal of Drug Policy;2024-07

2. How do patients feel during the first 72 h after initiating long‐acting injectable buprenorphine? An embodied qualitative analysis;Addiction;2023-03-08

3. Critical access medication for opioid use disorder (MOUD) treatment facilities in the continental United States;Drug and Alcohol Dependence Reports;2023-03

4. Qualitative study of patients’ decisions to initiate injectable depot buprenorphine for opioid use disorder: the role of information and other factors;Drugs: Education, Prevention and Policy;2023-01-10

5. Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation;BMJ Open;2022-10